Literature DB >> 2149493

Concentrations of teicoplanin in serum and atrial appendages of patients undergoing cardiac surgery.

M G Bergeron1, R Saginur, D Desaulniers, S Trottier, W Goldstein, P Foucault, C Lessard.   

Abstract

The concentrations of teicoplanin in sera and heart tissues of 49 patients undergoing coronary bypass were measured. Each patient received a 6- or 12-mg/kg dose of teicoplanin administered in a slow intravenous bolus injection over 3 to 5 min beginning at the time of induction of anesthesia. Mean +/- standard error of the mean concentrations in serum were, for the two doses, respectively, 58.1 +/- 1.7 and 123.3 +/- 7.4 micrograms/ml 5 min after administration and 22.2 +/- 0.7 and 56.5 +/- 2.8 micrograms/ml at the time of removal of atrial appendages. Mean +/- standard error of the mean concentrations in tissue were 70.6 +/- 1.7 and 139.8 +/- 2.2 micrograms/g, respectively, giving mean tissue/serum ratios of 3.7 +/- 0.3 and 2.8 +/- 0.2, respectively. Teicoplanin penetrates heart tissue readily and reaches levels in the serum far in excess of the MICs for most pathogens that have been found to cause infections following open heart surgery.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2149493      PMCID: PMC171908          DOI: 10.1128/AAC.34.9.1699

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Intraphagocytic penetration of antibiotics.

Authors:  P Van der Auwera; T Matsumoto; M Husson
Journal:  J Antimicrob Chemother       Date:  1988-08       Impact factor: 5.790

2.  Comparison of the in vitro activities of teichomycin A2 and vancomycin against staphylococci and enterococci.

Authors:  M H Cynamon; P A Granato
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

3.  In vitro activity and human pharmacokinetics of teicoplanin.

Authors:  L Verbist; B Tjandramaga; B Hendrickx; A Van Hecken; P Van Melle; R Verbesselt; J Verhaegen; P J De Schepper
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

4.  Investigations on the flucloxacillin levels in human serum, lung tissue, pericardial fluid and heart tissue.

Authors:  I J Kiss; E Faragó; A Gömöry; J Szamaránszky
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1980-09

5.  Comparison of cephalothin and cefamandole prophylaxis during insertion of prosthetic heart valves.

Authors:  G L Archer; R E Polk; R J Duma; R Lower
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

6.  Epidemiology of nosocomial infections caused by methicillin-resistant Staphylococcus aureus.

Authors:  R L Thompson; I Cabezudo; R P Wenzel
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

7.  In vitro activity of teichomycin compared with those of other antibiotics.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

8.  Comparative in vitro activities of teichomycin and other antibiotics against JK diphtheroids.

Authors:  L Jadeja; V Fainstein; B LeBlanc; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

9.  Concentrations of fusidic acid, cloxacillin, and cefamandole in sera and atrial appendages of patients undergoing cardiac surgery.

Authors:  M G Bergeron; D Desaulniers; C Lessard; M Lemieux; J P Després; J Métras; G Raymond; G Brochu
Journal:  Antimicrob Agents Chemother       Date:  1985-06       Impact factor: 5.191

10.  Penetration of pefloxacin in human heart valves.

Authors:  N Brion; A Lessana; F Mosset; J J Lefevre; G Montay
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

View more
  3 in total

1.  Prophylaxis with teicoplanin and cefuroxime reduces the rate of prosthetic joint infection after primary arthroplasty.

Authors:  Eduard Tornero; Sebastian García-Ramiro; Juan C Martínez-Pastor; Guillem Bori; Jordi Bosch; Laura Morata; Marta Sala; Misericordia Basora; Josep Mensa; Alex Soriano
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

Review 2.  Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D H Peters
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

Review 3.  Teicoplanin-A New Use for an Old Drug in the COVID-19 Era?

Authors:  Vladimir Vimberg
Journal:  Pharmaceuticals (Basel)       Date:  2021-11-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.